相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Liraglutide Reduces CNS Activation in Response to Visual Food Cues Only After Short-term Treatment in Patients With Type 2 Diabetes
Jennifer S. ten Kulve et al.
DIABETES CARE (2016)
Dumping Syndrome: A Review of the Current Concepts of Pathophysiology, Diagnosis, and Treatment
Patrick Berg et al.
DIGESTIVE DISEASES AND SCIENCES (2016)
GLP-1R Agonists Promote Normal and Neoplastic Intestinal Growth through Mechanisms Requiring Fgf7
Jacqueline A. Koehler et al.
CELL METABOLISM (2015)
Hyperglycemia Potentiates the Slowing of Gastric Emptying Induced by Exogenous GLP-1
Mark P. Plummer et al.
DIABETES CARE (2015)
Effects of Insulin Glargine and Liraglutide Therapy on Liver Fat as Measured by Magnetic Resonance in Patients With Type 2 Diabetes: A Randomized Trial
An Tang et al.
DIABETES CARE (2015)
Effect of sitagliptin on intrahepatic lipid content and body fat in patients with type 2 diabetes
Hiroyuki Kato et al.
DIABETES RESEARCH AND CLINICAL PRACTICE (2015)
Incretin-based therapies: where will we be 50 years from now?
Juris J. Meier et al.
DIABETOLOGIA (2015)
Management of hyperglycaemia in type 2 diabetes, 2015: a patient-centred approach. Update to a Position Statement of the American Diabetes Association and the European Association for the Study of Diabetes
Silvio E. Inzucchi et al.
DIABETOLOGIA (2015)
Relationships of Early And Late Glycemic Responses With Gastric Emptying During An Oral Glucose Tolerance Test
Chinmay S. Marathe et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2015)
A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management
Xavier Pi-Sunyer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes
Jennifer B. Green et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome
Marc A. Pfeffer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Effects of Glucagon-Like Peptide-1 Receptor Agonists on Weight Loss in Patients with Type 2 Diabetes: A Systematic Review and Network Meta-Analysis
Feng Sun et al.
JOURNAL OF DIABETES RESEARCH (2015)
Once-weekly DPP-4 inhibitors: do they meet an unmet need?
Andre J. Scheen
LANCET DIABETES & ENDOCRINOLOGY (2015)
Sucralose enhances GLP-1 release and lowers blood glucose in the presence of carbohydrate in healthy subjects but not in patients with type 2 diabetes
S. Temizkan et al.
EUROPEAN JOURNAL OF CLINICAL NUTRITION (2015)
Pilot study of liraglutide effects in non-alcoholic steatohepatitis and non-alcoholic fatty liver disease with glucose intolerance in Japanese patients (LEAN-J)
Yuichiro Eguchi et al.
HEPATOLOGY RESEARCH (2015)
Physiology and Pharmacology of the Enteroendocrine Hormone Glucagon-Like Peptide-2
Daniel J. Drucker et al.
ANNUAL REVIEW OF PHYSIOLOGY, VOL 76 (2014)
Defining the Role of GLP-1 in the Enteroinsulinar Axis in Type 2 Diabetes Using DPP-4 Inhibition and GLP-1 Receptor Blockade
Benedikt A. Aulinger et al.
DIABETES (2014)
Comparative Effects of Prolonged and Intermittent Stimulation of the Glucagon-Like Peptide 1 Receptor on Gastric Emptying and Glycemia
Mahesh M. Umapathysivam et al.
DIABETES (2014)
Sitagliptin, a DPP-4 Inhibitor, Acutely Inhibits Intestinal Lipoprotein Particle Secretion in Healthy Humans
Changting Xiao et al.
DIABETES (2014)
The Human GLP-1 Analogs Liraglutide and Semaglutide: Absence of Histopathological Effects on the Pancreas in Nonhuman Primates
Carsten F. Gotfredsen et al.
DIABETES (2014)
Glucagon-Like Peptide 1 Attenuates the Acceleration of Gastric Emptying Induced by Hypoglycemia in Healthy Subjects
Mark P. Plummer et al.
DIABETES CARE (2014)
Incidence of Pancreatitis and Pancreatic Cancer in a Randomized Controlled Multicenter Trial (SAVOR-TIMI 53) of the Dipeptidyl Peptidase-4 Inhibitor Saxagliptin
Itamar Raz et al.
DIABETES CARE (2014)
A prospective, claims-based assessment of the risk of pancreatitis and pancreatic cancer with liraglutide compared to other antidiabetic drugs
D. Funch et al.
DIABETES OBESITY & METABOLISM (2014)
Reanalysis of study of pancreatic effects of incretin therapy: methodological deficiencies
S. Bonner-Weir et al.
DIABETES OBESITY & METABOLISM (2014)
Activation of glucagon-like peptide-1 receptor inhibits tumourigenicity and metastasis of human pancreatic cancer cells via PI3K/Akt pathway
H. Zhao et al.
DIABETES OBESITY & METABOLISM (2014)
Sitagliptin attenuates methionine/choline-deficient diet-induced steatohepatitis
Yun-A. Jung et al.
DIABETES RESEARCH AND CLINICAL PRACTICE (2014)
Risk of pancreatitis in patients treated with incretin-based therapies
Juris J. Meier et al.
DIABETOLOGIA (2014)
Characterization of the Exocrine Pancreas in the Male Zucker Diabetic Fatty Rat Model of Type 2 Diabetes Mellitus Following 3 Months of Treatment With Sitagliptin
Thomas Forest et al.
ENDOCRINOLOGY (2014)
GLP-1 Receptor Localization in Monkey and Human Tissue: Novel Distribution Revealed With Extensively Validated Monoclonal Antibody
Charles Pyke et al.
ENDOCRINOLOGY (2014)
Effects of Exogenous Glucagon-Like Peptide-1 on the Blood Pressure, Heart Rate, Mesenteric Blood Flow, and Glycemic Responses to Intraduodenal Glucose in Healthy Older Subjects
Laurence G. Trahair et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2014)
Effects of glucagon-like peptide 1 on appetite and body weight: focus on the CNS
L. van Bloemendaal et al.
JOURNAL OF ENDOCRINOLOGY (2014)
Exogenous glucagon-like peptide 1 reduces contractions in human colon circular muscle
Antonella Amato et al.
JOURNAL OF ENDOCRINOLOGY (2014)
Linagliptin alleviates hepatic steatosis and inflammation in a mouse model of non-alcoholic steatohepatitis
Thomas Klein et al.
MEDICAL MOLECULAR MORPHOLOGY (2014)
Pancreatic Safety of Incretin-Based Drugs - FDA and EMA Assessment
Amy G. Egan et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Incretin treatment and risk of pancreatitis in patients with type 2 diabetes mellitus: systematic review and meta-analysis of randomised and non-randomised studies
Ling Li et al.
BMJ-BRITISH MEDICAL JOURNAL (2014)
Incretin therapies and risk of hospital admission for acute pancreatitis in an unselected population of European patients with type 2 diabetes: a case-control study
Carlo B. Giorda et al.
LANCET DIABETES & ENDOCRINOLOGY (2014)
One year of sitagliptin treatment protects against islet amyloid-associated β-cell loss and does not induce pancreatitis or pancreatic neoplasia in mice
Kathryn Aston-Mourney et al.
AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM (2013)
The effect of exogenous GLP-1 on food intake is lost in male truncally vagotomized subjects with pyloroplasty
Astrid Plamboeck et al.
AMERICAN JOURNAL OF PHYSIOLOGY-GASTROINTESTINAL AND LIVER PHYSIOLOGY (2013)
Increased Risk of Colorectal Cancer After Obesity Surgery
Maryam Derogar et al.
ANNALS OF SURGERY (2013)
Molecular mechanisms of incretin hormone secretion
Marina Ezcurra et al.
CURRENT OPINION IN PHARMACOLOGY (2013)
Marked Expansion of Exocrine and Endocrine Pancreas With Incretin Therapy in Humans With Increased Exocrine Pancreas Dysplasia and the Potential for Glucagon-Producing Neuroendocrine Tumors
Alexandra E. Butler et al.
DIABETES (2013)
Relationships Between Gastric Emptying, Postprandial Glycemia, and Incretin Hormones
Chinmay S. Marathe et al.
DIABETES CARE (2013)
No evidence of drug-induced pancreatitis in rats treated with exenatide for 13 weeks
K. Tatarkiewicz et al.
DIABETES OBESITY & METABOLISM (2013)
Studies in rodents with the dipeptidyl peptidase-4 inhibitor vildagliptin to evaluate possible drug-induced pancreatic histological changes that are predictive of pancreatitis and cancer development in man
S. J. Busch et al.
DIABETES OBESITY & METABOLISM (2013)
Liraglutide suppresses postprandial triglyceride and apolipoprotein B48 elevations after a fat-rich meal in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, cross-over trial
K. Hermansen et al.
DIABETES OBESITY & METABOLISM (2013)
A low-grade increase of serum pancreatic exocrine enzyme levels by dipeptidyl peptidase-4 inhibitor in patients with type 2 diabetes
Hirotake Tokuyama et al.
DIABETES RESEARCH AND CLINICAL PRACTICE (2013)
An Analysis of Characteristics of Subjects Examined for Incretin Effects on Pancreatic Pathology
Evis Harja et al.
DIABETES TECHNOLOGY & THERAPEUTICS (2013)
Direct effect of GLP-1 infusion on endogenous glucose production in humans
M. Seghieri et al.
DIABETOLOGIA (2013)
Do current incretin mimetics exploit the full therapeutic potential inherent in GLP-1 receptor stimulation?
M. A. Nauck et al.
DIABETOLOGIA (2013)
Glucagon-like peptide-1 receptor agonist treatment reduces beta cell mass in normoglycaemic mice
J. H. Ellenbroek et al.
DIABETOLOGIA (2013)
Dipeptidyl Peptidase 4-Deficient Rats Have Improved Bile Secretory Function in High Fat Diet-Induced Steatosis (vol 58, pg 172, 2013)
Shani Ben-Shlomo et al.
DIGESTIVE DISEASES AND SCIENCES (2013)
GLP-1 Receptor Activation Indirectly Reduces Hepatic Lipid Accumulation But Does Not Attenuate Development of Atherosclerosis in Diabetic Male ApoE(-/-) Mice
Naim Panjwani et al.
ENDOCRINOLOGY (2013)
Glucagon-like peptide-1 as a treatment for chemotherapy-induced mucositis
Hannelouise Kissow et al.
GUT (2013)
Effect of the GLP-1 analog liraglutide on satiation and gastric sensorimotor function during nutrient-drink ingestion
A. Rotondo et al.
INTERNATIONAL JOURNAL OF OBESITY (2013)
Alogliptin after Acute Coronary Syndrome in Patients with Type 2 Diabetes
William B. White et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Effects of lixisenatide once daily on gastric emptying in type 2 diabetes - Relationship to postprandial glycemia
Martin Lorenz et al.
REGULATORY PEPTIDES (2013)
Acute effects of continuous infusions of glucagon-like peptide (GLP)-1, GLP-2 and the combination (GLP-1+GLP-2) on intestinal absorption in short bowel syndrome (SBS) patients. A placebo-controlled study
K. B. Madsen et al.
REGULATORY PEPTIDES (2013)
Dipeptidyl peptidase-4 inhibitor anagliptin facilitates restoration of dextran sulfate sodium-induced colitis
Shunya Mimura et al.
SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY (2013)
Glucagonlike Peptide 1-Based Therapies and Risk of Hospitalization for Acute Pancreatitis in Type 2 Diabetes Mellitus A Population-Based Matched Case-Control Study
Sonal Singh et al.
JAMA INTERNAL MEDICINE (2013)
The effects of sitagliptin on gastric emptying in healthy humans - a randomised, controlled study
J. E. Stevens et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2012)
The effects of 13 wk of liraglutide treatment on endocrine and exocrine pancreas in male and female ZDF rats: a quantitative and qualitative analysis revealing no evidence of drug-induced pancreatitis
Niels Vrang et al.
AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM (2012)
Effect of a glucagon-like peptide 1 analog, ROSE-010, on GI motor functions in female patients with constipation-predominant irritable bowel syndrome
Michael Camilleri et al.
AMERICAN JOURNAL OF PHYSIOLOGY-GASTROINTESTINAL AND LIVER PHYSIOLOGY (2012)
Exenatide, a Glucagon-like Peptide-1 Receptor Agonist, Acutely Inhibits Intestinal Lipoprotein Production in Healthy Humans
Changting Xiao et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2012)
Efficacy of Buspirone, a Fundus-Relaxing Drug, in Patients With Functional Dyspepsia
Jan Tack et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2012)
Chronic GLP-1 Receptor Activation by Exendin-4 Induces Expansion of Pancreatic Duct Glands in Rats and Accelerates Formation of Dysplastic Lesions and Chronic Pancreatitis in the KrasG12D Mouse Model
Belinda Gier et al.
DIABETES (2012)
The Human GLP-1 Analog Liraglutide and the Pancreas Evidence for the Absence of Structural Pancreatic Changes in Three Species
Niels C. B. Nyborg et al.
DIABETES (2012)
Liraglutide: short-lived effect on gastric emptyingulong lasting effects on body weight
J. Jelsing et al.
DIABETES OBESITY & METABOLISM (2012)
Relative risk of acute pancreatitis in initiators of exenatide twice daily compared with other anti-diabetic medication: a follow-up study
M. Wenten et al.
DIABETIC MEDICINE (2012)
ELEVATED AMYLASE AND LIPASE LEVELS IN PATIENTS USING GLUCAGONLIKE PEPTIDE-1 RECEPTOR AGONISTS OR DIPEPTIDYL-PEPTIDASE-4 INHIBITORS IN THE OUTPATIENT SETTING
Howard M. Lando et al.
ENDOCRINE PRACTICE (2012)
Impact of GLP-1 Receptor Agonists on Major Gastrointestinal Disorders for Type 2 Diabetes Mellitus: A Mixed Treatment Comparison Meta-Analysis
Feng Sun et al.
EXPERIMENTAL DIABETES RESEARCH (2012)
Sitagliptin Exerts an Antinflammatory Action
Antoine Makdissi et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2012)
Exenatide Exerts a Potent Antiinflammatory Effect
Ajay Chaudhuri et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2012)
The role of nausea in food intake and body weight suppression by peripheral GLP-1 receptor agonists, exendin-4 and liraglutide
Scott E. Kanoski et al.
NEUROPHARMACOLOGY (2012)
Improved Glycaemia Correlates with Liver Fat Reduction in Obese, Type 2 Diabetes, Patients Given Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists
Daniel J. Cuthbertson et al.
PLOS ONE (2012)
GLP-1 Receptor Activation Inhibits VLDL Production and Reverses Hepatic Steatosis by Decreasing Hepatic Lipogenesis in High-Fat-Fed APOE*3-Leiden Mice
Edwin T. Parlevliet et al.
PLOS ONE (2012)
Effect of exenatide on cholecystokinin-induced gallbladder emptying in fasting healthy subjects
Jutta Keller et al.
REGULATORY PEPTIDES (2012)
The Effectiveness of Liraglutide in Nonalcoholic Fatty Liver Disease Patients with Type 2 Diabetes Mellitus Compared to Sitagliptin and Pioglitazone
Takamasa Ohki et al.
SCIENTIFIC WORLD JOURNAL (2012)
Sitagliptin prevents the development of metabolic and hormonal disturbances, increased beta-cell apoptosis and liver steatosis induced by a fructose-rich diet in normal rats
Barbara Maiztegui et al.
CLINICAL SCIENCE (2011)
Diet-Induced Adipose Tissue Inflammation and Liver Steatosis Are Prevented by DPP-4 Inhibition in Diabetic Mice
Jun Shirakawa et al.
DIABETES (2011)
Rapid Tachyphylaxis of the Glucagon-Like Peptide 1-Induced Deceleration of Gastric Emptying in Humans
Michael A. Nauck et al.
DIABETES (2011)
A cohort study of acute pancreatitis in relation to exenatide use
D. D. Dore et al.
DIABETES OBESITY & METABOLISM (2011)
Glucagon-like peptide-1 (GLP-1) and the regulation of human invariant natural killer T cells: lessons from obesity, diabetes and psoriasis
A. E. Hogan et al.
DIABETOLOGIA (2011)
Effects of GLP-1 and Incretin-Based Therapies on Gastrointestinal Motor Function
Chinmay S. Marathe et al.
EXPERIMENTAL DIABETES RESEARCH (2011)
Pancreatitis, Pancreatic, and Thyroid Cancer With Glucagon-Like Peptide-1-Based Therapies
Michael Elashoff et al.
GASTROENTEROLOGY (2011)
Sitagliptin as a Novel Treatment Agent for Non-Alcoholic Fatty Liver Disease Patients with Type 2 Diabetes Mellitus
Tomoyuki Iwasaki et al.
HEPATO-GASTROENTEROLOGY (2011)
Glucagon-like peptide-1 receptor activation stimulates hepatic lipid oxidation and restores hepatic signalling alteration induced bya high-fat diet in nonalcoholic steatohepatitis
Gianluca Svegliati-Baroni et al.
LIVER INTERNATIONAL (2011)
Efficacy of the glucagon-like peptide-1 agonist exenatide in the treatment of short bowel syndrome
D. Kunkel et al.
NEUROGASTROENTEROLOGY AND MOTILITY (2011)
GLP-1 Analogs Reduce Hepatocyte Steatosis and Improve Survival by Enhancing the Unfolded Protein Response and Promoting Macroautophagy
Shvetank Sharma et al.
PLOS ONE (2011)
Involvement of endogenous glucagon-like peptide-1 in regulation of gastric motility and pancreatic endocrine secretion
Anne-Barbara Witte et al.
SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY (2011)
Exenatide does not evoke pancreatitis and attenuates chemically induced pancreatitis in normal and diabetic rodents
Krystyna Tatarkiewicz et al.
AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM (2010)
Comparative effects of telmisartan, sitagliptin and metformin alone or in combination on obesity, insulin resistance, and liver and pancreas remodelling in C57BL/6 mice fed on a very high-fat diet
Vanessa Souza-Mello et al.
CLINICAL SCIENCE (2010)
Effects of exogenous glucagon-like peptide-1 on gastric emptying and glucose absorption in the critically ill: Relationship to glycemia
Adam M. Deane et al.
CRITICAL CARE MEDICINE (2010)
Acute Pancreatitis in Type 2 Diabetes Treated With Exenatide or Sitagliptin
Rajesh Garg et al.
DIABETES CARE (2010)
Biochemical and histological effects of exendin-4 (exenatide) on the rat pancreas
J. S. Nachnani et al.
DIABETOLOGIA (2010)
The glucagon-like peptide 1 receptor is essential for postprandial lipoprotein synthesis and secretion in hamsters and mice
J. Hsieh et al.
DIABETOLOGIA (2010)
Diabetic gastroparesis: what we have learned and had to unlearn in the past 5 years
Purna Kashyap et al.
GUT (2010)
Evolution of Inflammation in Nonalcoholic Fatty Liver Disease: The Multiple Parallel Hits Hypothesis
Herbert Tilg et al.
HEPATOLOGY (2010)
Endogenous Glucagon-Like Peptide-1 Slows Gastric Emptying in Healthy Subjects, Attenuating Postprandial Glycemia
Adam M. Deane et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2010)
Peripheral motor action of glucagon-like peptide-1 through enteric neuronal receptors
A. Amato et al.
NEUROGASTROENTEROLOGY AND MOTILITY (2010)
Insulin-like actions of glucagon-like peptide-1: a dual receptor hypothesis
Eva Tomas et al.
TRENDS IN ENDOCRINOLOGY AND METABOLISM (2010)
Clinical trial: the glucagon-like peptide-1 analogue ROSE-010 for management of acute pain in patients with irritable bowel syndrome: a randomized, placebo-controlled, double-blind study
P. M. Hellstrom et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2009)
Effect of the artificial sweetener, sucralose, on gastric emptying and incretin hormone release in healthy subjects
Jing Ma et al.
AMERICAN JOURNAL OF PHYSIOLOGY-GASTROINTESTINAL AND LIVER PHYSIOLOGY (2009)
Glucagon-Like Peptide-1 Receptor Activation Modulates Pancreatitis-Associated Gene Expression But Does Not Modify the Susceptibility to Experimental Pancreatitis in Mice
Jacqueline A. Koehler et al.
DIABETES (2009)
Beneficial Endocrine but Adverse Exocrine Effects of Sitagliptin in the Human Islet Amyloid Polypeptide Transgenic Rat Model of Type 2 Diabetes Interactions With Metformin
Aleksey V. Matveyenko et al.
DIABETES (2009)
Exendin-4, a glucagon-like peptide 1 receptor agonist, protects cholangiocytes from apoptosis
M. Marzioni et al.
GUT (2009)
GLP-1 analogues: a new therapeutic approach to prevent ductopenia in cholangiopathies?
Ulrich Beuers et al.
GUT (2009)
The Extrapancreatic Effects of Glucagon-Like Peptide-1 and Related Peptides
Rania Abu-Hamdah et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2009)
Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6)
John B. Buse et al.
LANCET (2009)
GLP-1 regulates gastroduodenal motility involving cholinergic pathways
J. Schirra et al.
NEUROGASTROENTEROLOGY AND MOTILITY (2009)
Differential effect of PYY1-36 and PYY3-36 on gastric emptying in man
A. -B. Witte et al.
REGULATORY PEPTIDES (2009)
Effects of exenatide versus sitagliptin on postprandial glucose, insulin and glucagon secretion, gastric emptying, and caloric intake: a randomized, cross-over study
Ralph A. DeFronzo et al.
CURRENT MEDICAL RESEARCH AND OPINION (2008)
Patient-reported rating of gastrointestinal adverse effects during treatment of type 2 diabetes with the once-daily human GLP-1 analogue, liraglutide
M. Horowitz et al.
DIABETES OBESITY & METABOLISM (2008)
Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study
Daniel J. Drucker et al.
LANCET (2008)
GLP-1 suppresses gastrointestinal motility and inhibits the migrating motor complex in healthy subjects and patients with irritable bowel syndrome
P. M. Hellstrom et al.
NEUROGASTROENTEROLOGY AND MOTILITY (2008)
Ileal brake: A sensible food target for appetite control. A review
P. W. J. Maljaars et al.
PHYSIOLOGY & BEHAVIOR (2008)
Effect of exenatide on gastric emptying and relationship to postprandial glycemia in type 2 diabetes
Helle Linnebjerg et al.
REGULATORY PEPTIDES (2008)
The physiology of glucagon-like peptide 1
Jens Juul Holst
PHYSIOLOGICAL REVIEWS (2007)
Exendin-4, but not dipeptidyl peptidase IV inhibition, increases small intestinal mass in GK rats
Lotte Simonsen et al.
AMERICAN JOURNAL OF PHYSIOLOGY-GASTROINTESTINAL AND LIVER PHYSIOLOGY (2007)
Effects of dipeptidyl peptidase-4 inhibition on gastrointestinal function, meal appearance, and glucose metabolism in type 2 diabetes
Adrian Vella et al.
DIABETES (2007)
GLP-1 receptor expression in human tumors and human normal tissues:: Potential for in vivo targeting
Meike Koerner et al.
JOURNAL OF NUCLEAR MEDICINE (2007)
Effects of intravenous glucagon-like peptide-1 on gastric emptying and intragastric distribution in healthy subjects: Relationships with postprandial glycemic and insulinemic responses
TJ Little et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2006)
Endogenous glucagon-like peptide 1 controls endocrine pancreatic secretion and antro-pyloro-duodenal motility in humans
J Schirra et al.
GUT (2006)
Glucagon-like peptide-1 is involved in sodium and water homeostasis in humans
Jean-Pierre Gutzwiller et al.
DIGESTION (2006)
Vildagliptin, a dipeptidyl peptidase-IV inhibitor, improves model-assessed β-cell function in patients with type 2 diabetes
A Mari et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2005)
Erythromycin antagonizes the deceleration of gastric emptying by glucagon-like peptide 1 and unmasks its insulinotropic effect in healthy subjects
JJ Meier et al.
DIABETES (2005)
Secretion, degradation, and elimination of glucagon-like peptide 1 and gastric inhibitory polypeptide in patients with chronic renal insufficiency and healthy control subjects
JJ Meier et al.
DIABETES (2004)
Effectiveness of progressive dose-escalation of exenatide (exendin-4) in reducing dose-limiting side effects in subjects with type 2 diabetes
MS Fineman et al.
DIABETES-METABOLISM RESEARCH AND REVIEWS (2004)
Effect of variations in small intestinal glucose delivery on plasma glucose, insulin, and incretin hormones in healthy subjects and type 2 diabetes
DG O'Donovan et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2004)
Insulin-independent effects of GLP-1 on canine liver glucose metabolism: duration of infusion and involvement of hepatoportal region
D Dardevet et al.
AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM (2004)
Pathophysiology and treatment of functional dyspepsia
J Tack et al.
GASTROENTEROLOGY (2004)
Effects of glucagon-like peptide-1 (7-36)amide on motility and sensation of the proximal stomach in humans
J Schirra et al.
GUT (2002)
Prevalence of gastrointestinal symptoms associated with diabetes mellitus - A population-based survey of 15000 adults
P Bytzer et al.
ARCHIVES OF INTERNAL MEDICINE (2001)
Glucagon-like peptide 2 improves nutrient absorption and nutritional status in short-bowel patients with no colon
PB Jeppesen et al.
GASTROENTEROLOGY (2001)
Relationships of upper gastrointestinal motor and sensory function with glycemic control
CK Rayner et al.
DIABETES CARE (2001)
分享论文
